News

The phase III trial known as “Encore” enrolled 510 patients with evidence of active inflammation. The data showed that Tysabri (natalizumab) helped decrease disease activity and promote remission.

The company revealed details about the new drugs when it was updating investors and financial analysts on its vaccines division. GlaxoSmithKline said its Cervarix product for the prevention

Under the terms of the agreement, Novartis will undertake most of the further development and all commercialization activity for the compound which is currently undergoing phase II clinical

The company is said to have ended the partnership after a study revealed that the drug Daxas, an oral anti-inflammatory product, was not as effective as the two

According to the company, patients receiving Seroquel showed a statistically significant decrease in depression scores compared to patients taking placebo throughout the eight-week study. About 58% of the

Pharming has agreed to license AgReasearch its proprietary protein production technology, giving AgResearch responsibility for compound production, including the initial financing of the development program. AgResearch will also

The company had hoped that the phase III trial would prove Hyphanox to be as effective as the leading treatment for vaginal candidiasis, commonly known as vaginal yeast

Rotateq is an oral liquid vaccine that contains five human serotypes which cause most rotavirus disease worldwide. Zostavax is Merck’s investigational vaccine for the prevention of herpes zoster

The large-scale study conducted by Roche compared Pegasys to GlaxoSmithKline’s lamivudine to show that Pegasys can offer greater symptom improvement to patients with the most common form of